Volume | 196,113 |
|
|||||
News | - | ||||||
Day High | 10.70 | Low High |
|||||
Day Low | 10.09 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Inovio Pharmaceuticals Inc New | INO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.25 | 10.09 | 10.70 | 10.57 | 10.125 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,591 | 196,113 | $ 10.48 | $ 2,055,595 | - | 3.888 - 14.748 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:04:08 | 46 | $ 10.30 | USD |
Inovio Pharmaceuticals Inc New Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
246.32M | 23.37M | - | 832k | -135.12M | -5.78 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Inovio Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 10.20 | 10.8168 | 9.285 | 10.03 | 264,328 | 0.18 | 1.76% |
1 Month | 14.07 | 14.748 | 8.96 | 11.27 | 368,567 | -3.69 | -26.23% |
3 Months | 5.27 | 14.748 | 4.73 | 10.01 | 475,164 | 5.11 | 96.96% |
6 Months | 4.5852 | 14.748 | 3.888 | 7.24 | 2,015,308 | 5.79 | 126.38% |
1 Year | 9.8436 | 14.748 | 3.888 | 6.59 | 4,165,358 | 0.5364 | 5.45% |
3 Years | 82.80 | 123.96 | 3.888 | 35.63 | 4,918,088 | -72.42 | -87.46% |
5 Years | 45.72 | 426.00 | 3.888 | 122.41 | 9,078,949 | -35.34 | -77.30% |
Inovio Pharmaceuticals Description
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. |